

- **Investment Rationale**

*Purple Biotech is a clinical-stage public company committed to providing cancer patients with first-in-class, effective and durable therapies by overcoming tumor evasion and drug resistance.*

- **Business Strategy**

*We are focused on clinical development of oncology therapies. We source promising compounds and turn them into solutions for patients through fast-paced and well-designed clinical trials. By demonstrating clinical benefit of our Products, we generate value for patients, physicians, and for our shareholders*

- **Core Technology its uniqueness and its value proposition?**

*Targeting tumor cells is not sufficient to achieve sustainable responses and therefore we focus on innovative therapeutic approaches that also harness the Tumor Microenvironment to deliver transformative treatment options for cancer patients*

- **Product Profile/Pipeline**

***CM24** is a mAb targeting CEACAM1—an intercellular adhesion regulator of Fas-mediated apoptosis via interaction with  $\beta$ -catenin and enhances NK cell cytotoxicity against tumor cells. CM24 showed a favorable safety profile as monotherapy and promising efficacy signals in Pancreatic cancer patients in combination with nivolumab.*

***NT219** is a small molecule, dual inhibitor of IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways. NT219 demonstrated outstanding efficacy in preclinical models and is able to tackle resistance to multiple cancer treatments such as EGFR inhibitors or anti-PD1. NT219 has already shown promising signs of efficacy as a single agent and is being investigated in combination with cetuximab.*

### **What's Next?**

*We are advancing our Products through clinical development as a monotherapy and in combination with the current standard of care. We will complete phase 1 this year and plan to initiate additional expansion arms in the next 18 months.*

*We also actively seeking to expand our innovative oncology pipeline to maintain a balanced pipeline at different stages of development.*